BetterLife Pharma (BETRF) Notes Payables (2011 - 2026)

BetterLife Pharma has reported Notes Payables for 16 years, with the latest figure at $1.2 million in Q2 2026.

• On a quarterly basis, Notes Payables rose 100.48% year-over-year to $1.2 million in Q2 2026; TTM through Apr 2026 was $1.2 million, a 100.48% increase from a year earlier, with the FY2026 full-year figure at $1.0 million, down 5.21% from the prior year.
• Notes Payables was $1.2 million for Q2 2026 at BetterLife Pharma, up from $1.0 million in the prior quarter.
• The five-year high for Notes Payables was $1.2 million in Q2 2026, with the low at $114456.8 in Q1 2022.
• Average Notes Payables over 5 years is $677206.6, with a median of $686517.0 recorded in 2025.
• The sharpest annual moves came in 2022 and 2023: Notes Payables slumped 77.75% in 2022, then surged 524.6% in 2023.
• Over 5 years, Notes Payables stood at $554073.8 in 2022, then advanced by 27.7% to $707545.0 in 2023, then gained by 15.85% to $819657.3 in 2024, then fell by 16.24% to $686517.0 in 2025, then surged by 67.76% to $1.2 million in 2026.
• The last three Notes Payables figures came in at $1.2 million (Q2 2026), $1.0 million (Q1 2026), and $686517.0 (Q3 2025), per Business Quant data.